Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 in active peripheral spondyloarthritis
CTR20220216Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in peripheral spondyloarthritis (pSpA), reactive arthritis, sponsored by Novartis. Started Feb 2022; status: terminated.
02
Drugs
secukinumab
03
Conditions
peripheral spondyloarthritis (pSpA)reactive arthritis
Beyond the preview
Go deeper on CTR20220216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220216.